Calquence Approved for Chronic Lymphocytic Leukemia
In November 2019, the FDA approved a new treatment, Calquence, for patients with relapsed or refractory CLL or SLL.
Working with Your Treatment Team to Decide on the Best Options for You
LeukemiaLymphomaMultiple Myeloma
People who are diagnosed with blood cancer need to learn enough about it without being overwhelmed, and to take part in their treatment decisions. Communicate important personal information to your care team.
CAR T-Cell Therapy Emerging for Chronic Lymphocytic Leukemia
Chimeric antigen receptor (CAR) T-cell therapy could soon expand into chronic lymphocytic leukemia (CLL). Early clinical trials have shown responses in patients with CLL refractory to other therapies. Predicting which patients will respond is key to advancing CAR T-cell therapy into CLL.
Targeted Therapy Dominates CLL Treatment Landscape
Targeted therapy is at the forefront of chronic lymphocytic leukemia (CLL) treatment. In many cases, targeted agents offer superior outcomes to chemotherapy, with more manageable side effects. Multiple targeted therapy options are available, and some choices depend on certain molecular markers.
Cytogenetic Testing in Chronic Lymphocytic Leukemia
Cytogenetic testing is used to identify genomic aberrations in patients with chronic lymphocytic leukemia (CLL). It estimates a patient’s outcomes and can predict response to certain therapies, and therefore is recommended for all patients with CLL at diagnosis.
Acalabrutinib Alone or in Combination More Effective than Chemoimmunotherapy in Previously Untreated CLL
A new study presented at a major medical meeting showed that fewer patients with treatment-naïve chronic lymphocytic leukemia (CLL) who were treated with acalabrutinib alone or in combination with obinutuzumab had disease progression or died compared with a group of patients treated with the combination of obinutuzumab and chemotherapy.
Triplet Regimen with Acalabrutinib Is Highly Active in Untreated Chronic Lymphocytic Leukemia
A 3-drug regimen of acalabrutinib, venetoclax, and obinutuzumab was highly effective in removing all traces of disease from the bone marrow of patients with chronic lymphocytic leukemia, according to study results presented at the American Society of Hematology annual meeting.
Information Is Power: Targeted Therapies Extend Survival for Patients with Chronic Lymphocytic Leukemia
Until recently, the initial treatment for patients with CLL was chemotherapy alone. New targeted therapies are now available for use as the first treatment for CLL. At the 2019 ASCO meeting, 2 experts discussed the benefits of these new treatments.
Tibsovo Approved for First-Line Treatment of Patients with Acute Myeloid Leukemia and IDH1 Mutation
FDA Approvals, News & UpdatesLeukemia
In May 2019, the FDA approved Tibsovo for the treatment of older patients with newly diagnosed acute myeloid leukemia (AML) and an IDH1 mutation, or for patients with AML who are unable to use intensive chemotherapy.
Several Chemo-Free Combination Therapies Now Available for Patients with Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults. Recently, several new drug combinations without chemotherapy have been approved by the FDA for patients with CLL, providing patients new options when their cancer stops responding to current treatment.
Page 4 of 7
Results 31 - 40 of 62

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.